Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16564555 | 0.91 | ROCK2 (0.58) | ROCK2SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL4116438 | 0.90 | CNR1 (0.61) | ROCK2SMN1; SMN2ROCK1KDRMEN1 | |
| SCHEMBL4130093 | 0.85 | AURKA (0.54) | ROCK2ROCK1HIF1AKDRNAMPT | |
| SCHEMBL4124079 | 0.84 | MAPK1 (0.69) | ROCK2KDRNAMPTLMNAAURKA | |
| SCHEMBL4124949 | 0.84 | MTOR (0.55) | ROCK2ROCK1KDRNAMPTAURKA | |
| SCHEMBL4122172 | 0.84 | JAK2 (0.64) | ROCK2KDRNAMPTAURKAAURKB | |
| SCHEMBL12907153 | 0.83 | SMN1; SMN2 (0.67) | ROCK2SMN1; SMN2ROCK1ALDH1A1LMNA | |
| SCHEMBL4118023 | 0.82 | MAPK1 (0.49) | ROCK2SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL4116172 | 0.82 | MAPK1 (0.52) | ROCK2SMN1; SMN2ROCK1NAMPTMEN1 | |
| SCHEMBL4124726 | 0.81 | ROCK2 (0.53) | ROCK2SMN1; SMN2NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040701-B1 | AMINOINDAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | claimed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | claimed |
| EP-2040701-B1 | AMINOINDAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| CN-101489551-A | Aminoindazole urea derivatives | MERCK PATENT GMBH (DE) | 2009-07-22 | — | — | CN | disclosed |
| WO-2008009335-A2 | AMINOINDAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | ROCK2 635/4885SMN1; SMN2 4645/4885ROCK1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.